Beginning in 2014, Britain's National Institute for Health and Clinical Excellence will approve and price drugs based on broader measures, including the benefits to society. Firms with innovative, badly needed or highly effective medications, for example, could command higher prices. The new value-based initiative will replace the current system that caps the maximum return on investments that drug companies can earn.

Full Story:

Related Summaries